Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2016
At a glance
- Drugs L19 TNF fusion protein (Primary) ; Doxorubicin
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Philogen
- 14 Nov 2016 Planned End Date changed from 1 Feb 2016 to 1 Jun 2018.
- 14 Nov 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jun 2018.
- 07 Mar 2014 New trial record